Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results
» Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results PTIDec 17, 2020, 09:18 IST CovaxinBharat Biotech Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events. The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent s...